Silk Road Medical, Inc (SILK)

Market Cap	719.64M
Revenue (ttm)	177.13M
Net Income (ttm)	-55.74M
Shares Out	39.17M
EPS (ttm)	-1.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	185,983
Open	18.15
Previous Close	19.44
Day's Range	16.80 - 18.75
52-Week Range	6.08 - 43.52
Beta	1.48
Analysts	Buy
Price Target	24.10 (+31.55%)
Earnings Date	Apr 30, 2024

About SILK

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid arte...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 4, 2019
• Employees: 474
• Stock Exchange: NASDAQ
• Ticker Symbol: SILK

Financial Performance

In 2023, SILK's revenue was $177.13 million, an increase of 27.77% compared to the previous year's $138.64 million. Losses were -$55.74 million, 1.33% more than in 2022.

Analyst Forecast

According to 12 analysts, the average rating for SILK stock is "Buy." The 12-month stock price forecast is $24.1, which is an increase of 31.55% from the latest price.

Price Target

$24.1

(31.55% upside)

Analyst Consensus: Buy